PHVS vs. CNTX, GRFS, LVTX, MYNZ, NLSP, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
In the previous week, Pharvaris had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 15 mentions for Pharvaris and 11 mentions for Context Therapeutics. Pharvaris' average media sentiment score of 1.10 beat Context Therapeutics' score of 0.14 indicating that Context Therapeutics is being referred to more favorably in the media.
Pharvaris received 21 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 64.71% of users gave Pharvaris an outperform vote while only 63.16% of users gave Context Therapeutics an outperform vote.
Pharvaris is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
Context Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.02, indicating that its share price is 402% less volatile than the S&P 500.
14.0% of Context Therapeutics shares are owned by institutional investors. 9.4% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Context Therapeutics' return on equity of -39.67% beat Pharvaris' return on equity.
Context Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 321.35%. Pharvaris has a consensus price target of $31.50, suggesting a potential upside of 45.77%. Given Pharvaris' stronger consensus rating and higher possible upside, research analysts plainly believe Context Therapeutics is more favorable than Pharvaris.
Summary
Context Therapeutics beats Pharvaris on 9 of the 15 factors compared between the two stocks.
Get Pharvaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharvaris Competitors List
Related Companies and Tools
